Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Parkinson's Disease

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    April 2021
  1. BLAUWENDRAAT C, Iwaki H, Makarious MB, Bandres-Ciga S, et al
    Investigation of Autosomal Genetic Sex Differences in Parkinson's disease.
    Ann Neurol. 2021 Apr 26. doi: 10.1002/ana.26090.
    PubMed     Abstract available


  2. RUSZ J, Hlavnicka J, Novotny M, Tykalova T, et al
    Speech biomarkers in rapid eye movement sleep behaviour disorder and Parkinson's disease.
    Ann Neurol. 2021 Apr 15. doi: 10.1002/ana.26085.
    PubMed     Abstract available


    March 2021
  3. ROSEBRAUGH M, Voight EA, Moussa EM, Jameel F, et al
    Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson's disease.
    Ann Neurol. 2021 Mar 26. doi: 10.1002/ana.26073.
    PubMed     Abstract available


  4. ELIAS GJB, Boutet A, Joel SE, Germann J, et al
    Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy.
    Ann Neurol. 2021;89:426-443.
    PubMed     Abstract available


    February 2021
  5. LE GUEN Y, Napolioni V, Belloy ME, Yu E, et al
    Common X-chromosome variants are associated with Parkinson's disease risk.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26051.
    PubMed     Abstract available


  6. JENSEN MP, Jacobs BM, Dobson R, Bandres-Ciga S, et al
    Lower lymphocyte count is associated with increased risk of Parkinson's disease.
    Ann Neurol. 2021 Feb 2. doi: 10.1002/ana.26034.
    PubMed     Abstract available


  7. RAHAYEL S, Postuma RB, Montplaisir J, Misic B, et al
    A Prodromal Brain-Clinical Pattern of Cognition in Synucleinopathies.
    Ann Neurol. 2021;89:341-357.
    PubMed     Abstract available


  8. STANG CD, Mullan AF, Hajeb M, Camerucci E, et al
    Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt Alpha-Synucleinopathies.
    Ann Neurol. 2021;89:293-303.
    PubMed     Abstract available


    January 2021
  9. ANDERSEN MS, Bandres-Ciga S, Reynolds RH, Hardy J, et al
    Heritability enrichment implicates microglia in Parkinson's disease pathogenesis.
    Ann Neurol. 2021 Jan 27. doi: 10.1002/ana.26032.
    PubMed     Abstract available


    December 2020
  10. YAU WY, Sullivan R, Rocca C, Cali E, et al
    NOTCH2NLC Intermediate-length Repeat Expansion and Parkinson's Disease in Patients of European Descent.
    Ann Neurol. 2020 Dec 30. doi: 10.1002/ana.26003.
    PubMed    


  11. SHI CH, Fan Y, Xu YM
    Reply to "NOTCH2NLC Intermediate-length Repeat Expansion and Parkinson's Disease".
    Ann Neurol. 2020 Dec 30. doi: 10.1002/ana.26005.
    PubMed    


  12. CAVALLIERI F, Fraix V, Bove F, Mulas D, et al
    Predictors of long-term outcome of subthalamic stimulation in Parkinson disease.
    Ann Neurol. 2020 Dec 21. doi: 10.1002/ana.25994.
    PubMed     Abstract available


  13. TAN AH, Chong CW, Lim SY, Yap IKS, et al
    Gut microbial ecosystem in Parkinson's disease: New clinico-biological insights from multi-omics.
    Ann Neurol. 2020 Dec 3. doi: 10.1002/ana.25982.
    PubMed     Abstract available


  14. SHEN L, Jiang C, Hubbard CS, Ren J, et al
    Subthalamic Nucleus Deep Brain Stimulation Modulates 2 Distinct Neurocircuits.
    Ann Neurol. 2020;88:1178-1193.
    PubMed     Abstract available


    November 2020
  15. LEE JY, Ahn J, Shin J, Jeon B, et al
    Parafovea change and dopamine loss in the retina with Parkinson's disease.
    Ann Neurol. 2020 Nov 24. doi: 10.1002/ana.25972.
    PubMed    


    October 2020
  16. KIM CY, Wirth T, Hubsch C, Nemeth AH, et al
    Reply to "PPP2R5D genetic mutations and early-onset parkinsonism".
    Ann Neurol. 2020 Oct 24. doi: 10.1002/ana.25945.
    PubMed    


  17. MURUETA-GOYENA A, Del Pino R, Galdos M, Arana B, et al
    Retinal thickness predicts the risk of cognitive decline in Parkinson's disease.
    Ann Neurol. 2020 Oct 24. doi: 10.1002/ana.25944.
    PubMed     Abstract available


  18. DULOVIC-MAHLOW M, Konig IR, Trinh J, Diaw SH, et al
    Discordant monozygotic Parkinson disease twins: Role of mitochondrial integrity.
    Ann Neurol. 2020 Oct 23. doi: 10.1002/ana.25942.
    PubMed     Abstract available


  19. WALKER IM, Riboldi GM, Drummond P, Saade-Lemus S, et al
    PPP2R5D genetic mutations and early-onset parkinsonism.
    Ann Neurol. 2020 Oct 23. doi: 10.1002/ana.25943.
    PubMed    


  20. ESPAY AJ, Marsili L, Mahajan A, Sturchio A, et al
    Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25923.
    PubMed     Abstract available


  21. SHI CH, Fan Y, Yang J, Yuan YP, et al
    NOTCH2NLC Intermediate-length Repeat Expansions are Associated with Parkinson's Disease.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25925.
    PubMed     Abstract available


  22. LESAGE S, Lunati A, Houot M, Romdhan SB, et al
    Characterization of Recessive Parkinson Disease in a Large Multicenter Study.
    Ann Neurol. 2020;88:843-850.
    PubMed     Abstract available


    September 2020
  23. NUBER S, Nam AY, Rajsombath MM, Cirka H, et al
    A stearoyl-CoA desaturase inhibitor prevents multiple Parkinson's disease-phenotypes in alpha-synuclein mice.
    Ann Neurol. 2020 Sep 29. doi: 10.1002/ana.25920.
    PubMed     Abstract available


  24. ORTUNO-LIZARAN I, Sanchez-Saez X, Lax P, Serrano GE, et al
    Dopaminergic retinal cell loss and visual dysfunction in Parkinson's disease.
    Ann Neurol. 2020 Sep 3. doi: 10.1002/ana.25897.
    PubMed     Abstract available


  25. SINGER W, Schmeichel AM, Shahnawaz M, Schmelzer JD, et al
    Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Ann Neurol. 2020;88:503-512.
    PubMed     Abstract available


    August 2020
  26. WILLIAMS DM, Bandres-Ciga S, Heilbron K, Hinds D, et al
    Evaluating lipid-lowering drug targets for Parkinson's disease prevention with Mendelian randomization.
    Ann Neurol. 2020 Aug 25. doi: 10.1002/ana.25880.
    PubMed     Abstract available


  27. CHUNG CL, Mak MK, Hallett M
    Transcranial magnetic stimulation promotes gait training in Parkinson's disease.
    Ann Neurol. 2020 Aug 22. doi: 10.1002/ana.25881.
    PubMed     Abstract available


  28. PEBALL M, Krismer F, Knaus HG, Djamshidian A, et al
    Non-motor symptoms in Parkinson s disease are reduced by nabilone.
    Ann Neurol. 2020 Aug 5. doi: 10.1002/ana.25864.
    PubMed     Abstract available


  29. KIM CY, Wirth T, Hubsch C, Nemeth AH, et al
    Early-onset parkinsonism is a manifestation of the PPP2R5D p.E200K mutation.
    Ann Neurol. 2020 Aug 3. doi: 10.1002/ana.25863.
    PubMed     Abstract available


    July 2020
  30. MARIN-LAHOZ J, Sampedro F, Martinez-Horta S, Pagonabarraga J, et al
    Corrigendum: Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease.
    Ann Neurol. 2020;88:205.
    PubMed    


    June 2020
  31. IRWIN DJ, Felder J, Coffey CS, Caspell-Garcia C, et al
    Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Ann Neurol. 2020 Jun 16. doi: 10.1002/ana.25811.
    PubMed     Abstract available


  32. IRMEN F, Horn A, Mosley P, Perry A, et al
    Left Prefrontal Connectivity Links Subthalamic Stimulation with Depressive Symptoms.
    Ann Neurol. 2020;87:962-975.
    PubMed     Abstract available


  33. MONZON-SANDOVAL J, Poggiolini I, Ilmer T, Wade-Martins R, et al
    Human-Specific Transcriptome of Ventral and Dorsal Midbrain Dopamine Neurons.
    Ann Neurol. 2020;87:853-868.
    PubMed     Abstract available


    May 2020
  34. LESAGE S, Lunati A, Houot M, Romdhan SB, et al
    Characterization of recessive Parkinson's disease in a large multicenter study.
    Ann Neurol. 2020 May 30. doi: 10.1002/ana.25787.
    PubMed     Abstract available


  35. FANTINI ML, Fedler J, Pereira B, Weintraub D, et al
    Is RBD a risk factor for impulse control disorder in Parkinson's disease?
    Ann Neurol. 2020 May 28. doi: 10.1002/ana.25798.
    PubMed     Abstract available


  36. HEINZEL S, Aho VTE, Suenkel U, von Thaler AK, et al
    Gut microbiome signatures of risk and prodromal markers of Parkinson's disease.
    Ann Neurol. 2020 May 22. doi: 10.1002/ana.25788.
    PubMed     Abstract available


    April 2020
  37. KROHN L, Wu RYJ, Heilbron K, Ruskey JA, et al
    Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies.
    Ann Neurol. 2020;87:584-598.
    PubMed     Abstract available


    March 2020
  38. WHITE DL, Kunik ME, Yu H, Lin HL, et al
    Post-traumatic stress disorder is associated with further increased Parkinson's disease risk in veterans with traumatic brain injury.
    Ann Neurol. 2020 Mar 30. doi: 10.1002/ana.25726.
    PubMed     Abstract available


    February 2020
  39. MORO E, Bellot E, Meoni S, Pelissier P, et al
    Visual dysfunction of the superior colliculus in de novo Parkinsonian patients.
    Ann Neurol. 2020 Feb 6. doi: 10.1002/ana.25696.
    PubMed     Abstract available


  40. LOPEZ G, Eisenberg DP, Gregory MD, Ianni AM, et al
    Longitudinal positron emission tomography of dopamine synthesis in subjects with GBA1 mutations.
    Ann Neurol. 2020 Feb 6. doi: 10.1002/ana.25692.
    PubMed     Abstract available


    January 2020
  41. MATUSKEY D, Tinaz S, Wilcox KC, Naganawa M, et al
    Synaptic changes in Parkinson's disease assessed with in-vivo imaging.
    Ann Neurol. 2020 Jan 17. doi: 10.1002/ana.25682.
    PubMed     Abstract available


  42. KROHN L, Ozturk TN, Vanderperre B, Ouled Amar Bencheikh B, et al
    Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies.
    Ann Neurol. 2020;87:139-153.
    PubMed     Abstract available


    September 2019
  43. MAETZLER W, Del Din S, Elshehabi M, Galna B, et al
    Reply to Quantitative motor functioning in prodromal Parkinson's Disease (ANA-19-0978).
    Ann Neurol. 2019 Sep 30. doi: 10.1002/ana.25605.
    PubMed    


  44. DOMMERSHUIJSEN LJ, Ikram MK, Darweesh SKL
    Quantitative motor functioning in prodromal Parkinson's disease.
    Ann Neurol. 2019 Sep 30. doi: 10.1002/ana.25606.
    PubMed    


    August 2019
  45. KUMMER BR, Diaz I, Wu X, Aaroe AE, et al
    Associations between cerebrovascular risk factors and parkinson disease.
    Ann Neurol. 2019 Aug 29. doi: 10.1002/ana.25564.
    PubMed     Abstract available


  46. MARIN-LAHOZ J, Sampedro F, Martinez-Horta S, Pagonabarraga J, et al
    Depression as a risk factor for impulse control disorders in Parkinson's disease.
    Ann Neurol. 2019 Aug 15. doi: 10.1002/ana.25581.
    PubMed     Abstract available


  47. DEMBEK TA, Roediger J, Horn A, Reker P, et al
    Probabilistic Sweetspots Predict Motor Outcome for DBS in Parkinson's Disease.
    Ann Neurol. 2019 Aug 3. doi: 10.1002/ana.25567.
    PubMed     Abstract available


  48. OUZREN N, Delcambre S, Ghelfi J, Seibler P, et al
    Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation Carriers.
    Ann Neurol. 2019;86:324-326.
    PubMed    


  49. BAKSHI R, Macklin EA, Schwarzschild MA
    Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers".
    Ann Neurol. 2019;86:326-327.
    PubMed    


    July 2019
  50. GROZDANOV V, Bousset L, Hoffmeister M, Bliederhaeuser C, et al
    Increased immune activation by pathologic alpha-synuclein in Parkinson's Disease.
    Ann Neurol. 2019 Jul 25. doi: 10.1002/ana.25557.
    PubMed     Abstract available


  51. DEL DIN S, Elshehabi M, Galna B, Hobert M, et al
    Gait analysis with wearables predicts conversion to Parkinson's disease.
    Ann Neurol. 2019 Jul 11. doi: 10.1002/ana.25548.
    PubMed     Abstract available


    June 2019
  52. VOLLSTEDT EJ, Kasten M, Klein C
    Using global team science to identify genetic Parkinson's disease worldwide.
    Ann Neurol. 2019 Jun 2. doi: 10.1002/ana.25514.
    PubMed    


  53. SAIKI S, Sasazawa Y, Fujimaki M, Kamagata K, et al
    A metabolic profile of polyamines in Parkinson's disease: a promising biomarker.
    Ann Neurol. 2019 Jun 2. doi: 10.1002/ana.25516.
    PubMed     Abstract available


  54. STROTZER QD, Anthofer JM, Faltermeier R, Brawanski AT, et al
    Deep brain stimulation: Connectivity profile for bradykinesia alleviation.
    Ann Neurol. 2019;85:852-864.
    PubMed     Abstract available


    April 2019
  55. SCHULZ J, Takousis P, Wohlers I, Itua IOG, et al
    Meta-analyses identify differentially expressed microRNAs in Parkinson's disease.
    Ann Neurol. 2019 Apr 16. doi: 10.1002/ana.25490.
    PubMed     Abstract available


  56. WESTENBERGER A, Reyes CJ, Saranza G, Dobricic V, et al
    A hexanucleotide repeat modifies expressivity of X-linked dystonia-parkinsonism.
    Ann Neurol. 2019 Apr 11. doi: 10.1002/ana.25488.
    PubMed     Abstract available


  57. TROPEA TF, Mak J, Guo MH, Xie SX, et al
    TMEM106B Effect on Cognition in Parkinson's Disease and Frontotemporal Dementia.
    Ann Neurol. 2019 Apr 11. doi: 10.1002/ana.25486.
    PubMed     Abstract available


    March 2019
  58. SCHREINER SJ, Imbach LL, Werth E, Poryazova R, et al
    Slow-wave sleep and motor progression in Parkinson disease.
    Ann Neurol. 2019 Mar 18. doi: 10.1002/ana.25459.
    PubMed     Abstract available


    February 2019
  59. CHRISTINE CW, Bankiewicz KS, Van Laar AD, Richardson RM, et al
    MRI-guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease.
    Ann Neurol. 2019 Feb 25. doi: 10.1002/ana.25450.
    PubMed     Abstract available


  60. VAN RUMUND A, Green AJ, Fairfoul G, Esselink RA, et al
    Alpha-synuclein RT-QuIC in the CSF of uncertain cases of parkinsonism.
    Ann Neurol. 2019 Feb 23. doi: 10.1002/ana.25447.
    PubMed     Abstract available


  61. GOLDMAN SM, Marek K, Ottman R, Meng C, et al
    Concordance for Parkinson's Disease in Twins: a 20-Year Update.
    Ann Neurol. 2019 Feb 20. doi: 10.1002/ana.25441.
    PubMed     Abstract available


  62. BAKSHI R, Macklin EA, Logan R, Zorlu MM, et al
    Higher urate in LRRK2 mutation carriers resistant to Parkinson's disease.
    Ann Neurol. 2019 Feb 13. doi: 10.1002/ana.25436.
    PubMed     Abstract available


  63. BOHNEN NI, Kanel P, Zhou Z, Koeppe RA, et al
    Cholinergic system changes of falls and freezing of gait in Parkinson disease.
    Ann Neurol. 2019 Feb 5. doi: 10.1002/ana.25430.
    PubMed     Abstract available


  64. COUGHLIN D, Xie SX, Liang M, Williams A, et al
    Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Ann Neurol. 2019;85:259-271.
    PubMed     Abstract available


    November 2018
  65. DU G, Lewis MM, Sica C, Kong L, et al
    Magnetic resonance T1w/T2w ratio: A parsimonious marker for Parkinson's disease.
    Ann Neurol. 2018 Nov 8. doi: 10.1002/ana.25376.
    PubMed     Abstract available


    October 2018
  66. ESPAY AJ, Morgante F, Merola A, Fasano A, et al
    Levodopa-induced dyskinesia in Parkinson disease: Current and Evolving Concepts.
    Ann Neurol. 2018 Oct 24. doi: 10.1002/ana.25364.
    PubMed     Abstract available


  67. AMATO N, Manconi M, Moller JC, Sarasso S, et al
    Levodopa-induced dyskinesia in Parkinson's disease: sleep matters.
    Ann Neurol. 2018 Oct 17. doi: 10.1002/ana.25360.
    PubMed     Abstract available


    September 2018
  68. SEARLES NIELSEN S, Gross A, Camacho-Soto A, Willis AW, et al
    beta2-adrenoreceptor medications and risk of Parkinson disease.
    Ann Neurol. 2018 Sep 17. doi: 10.1002/ana.25341.
    PubMed     Abstract available


    August 2018
  69. PIHLSTROM L, Blauwendraat C, Cappelletti C, Berge-Seidl V, et al
    A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.
    Ann Neurol. 2018 Aug 26. doi: 10.1002/ana.25274.
    PubMed     Abstract available


    July 2018
  70. KIA DA, Noyce AJ, White J, Speed D, et al
    Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease.
    Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25294.
    PubMed     Abstract available


  71. KOBYLECKI CJ, Nordestgaard BG, Afzal S
    Plasma urate and risk of Parkinson's disease: a Mendelian randomization study.
    Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25292.
    PubMed     Abstract available


    May 2018
  72. LUKIC S, Bisevac B, Krstic N
    Intriguing association of Parkinson disease and epileptic seizures.
    Ann Neurol. 2018 May 8. doi: 10.1002/ana.25257.
    PubMed    


  73. GRUNTZ K, Fuhr P, Meier C, Ruegg S, et al
    Reply to <<Intriguing association of Parkinson disease and epileptic seizures >>.
    Ann Neurol. 2018 May 8. doi: 10.1002/ana.25252.
    PubMed    


    April 2018
  74. KOTAGAL V, Spino C, Bohnen NI, Koeppe RA, et al
    Serotonin, beta-amyloid, and cognition in Parkinson disease.
    Ann Neurol. 2018 Apr 17. doi: 10.1002/ana.25236.
    PubMed     Abstract available


    March 2018
  75. JONIKAS M, Madill M, Mathy A, Zekoll T, et al
    Stem Cell modeling of Mitochondrial Parkinsonism reveals key functions of OPA1.
    Ann Neurol. 2018 Mar 31. doi: 10.1002/ana.25221.
    PubMed     Abstract available


    January 2018
  76. GRUNTZ K, Bloechliger M, Becker C, Jick SS, et al
    Parkinson's disease and the risk of epileptic seizures.
    Ann Neurol. 2018 Jan 25. doi: 10.1002/ana.25157.
    PubMed     Abstract available


    November 2017
  77. KAASINEN V, Vahlberg T
    Striatal dopamine in Parkinson's disease: A meta-analysis of imaging studies.
    Ann Neurol. 2017 Nov 22. doi: 10.1002/ana.25103.
    PubMed     Abstract available


  78. BURY AG, Pyle A, Elson JL, Greaves L, et al
    Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson's.
    Ann Neurol. 2017 Nov 17. doi: 10.1002/ana.25099.
    PubMed     Abstract available


    October 2017
  79. LEE Y, Oh JS, Chung SJ, Chung SJ, et al
    Does Smoking Impact Dopamine Neuronal Loss in de novo Parkinson's Disease?
    Ann Neurol. 2017 Oct 23. doi: 10.1002/ana.25082.
    PubMed    


  80. CAMACHO-SOTO A, Warden MN, Searles Nielsen S, Salter A, et al
    Traumatic Brain Injury in the Prodromal Period of Parkinson Disease: A Large Epidemiological Study Using Medicare Data.
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25074.
    PubMed     Abstract available


  81. CHUANG YH, Lee PC, Vlaar T, Mulot C, et al
    Pooled analysis of the HLA-DRB1 by smoking interaction in Parkinson's disease.
    Ann Neurol. 2017 Oct 5. doi: 10.1002/ana.25065.
    PubMed     Abstract available


  82. SCHONHAUT DR, McMillan CT, Spina S, Dickerson BC, et al
    18 F-flortaucipir tau PET distinguishes established progressive supranuclear palsy from controls and Parkinson's disease: A multicenter study.
    Ann Neurol. 2017 Oct 5. doi: 10.1002/ana.25060.
    PubMed     Abstract available


    September 2017
  83. STORZER L, Butz M, Hirschmann J, Abbasi O, et al
    Bicycling suppresses abnormal beta synchrony in the Parkinsonian basal ganglia.
    Ann Neurol. 2017 Sep 11. doi: 10.1002/ana.25047.
    PubMed     Abstract available


  84. STRANIERO L, Guella I, Cilia R, Parkkinen L, et al
    DNAJC12 and dopa-responsive non-progressive Parkinsonism.
    Ann Neurol. 2017 Sep 11. doi: 10.1002/ana.25048.
    PubMed     Abstract available


    August 2017
  85. IRANZO A, Santamaria J, Valldeoriola F, Serradell M, et al
    Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic REM sleep behavior disorder.
    Ann Neurol. 2017 Aug 22. doi: 10.1002/ana.25026.
    PubMed     Abstract available


    June 2017
  86. HORN A, Reich M, Vorwerk J, Li N, et al
    Connectivity predicts deep brain stimulation outcome in Parkinson's disease.
    Ann Neurol. 2017 Jun 6. doi: 10.1002/ana.24974.
    PubMed     Abstract available


    May 2017
  87. MUSACCHIO T, Rebenstorff M, Fluri F, Brotchie JM, et al
    STN-DBS is neuroprotective in the A53T alpha-synuclein Parkinson's disease rat model.
    Ann Neurol. 2017 May 3. doi: 10.1002/ana.24947.
    PubMed     Abstract available


    April 2017
  88. SEIDEL K, Bouzrou M, Heidemann N, Kruger R, et al
    Involvement of the cerebellum in Parkinson's disease and Dementia with Lewy bodies.
    Ann Neurol. 2017 Apr 25. doi: 10.1002/ana.24937.
    PubMed     Abstract available


    March 2017
  89. CHEN X, Chen H, Cai W, Maguire M, et al
    The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.
    Ann Neurol. 2017;81:395-406.
    PubMed     Abstract available


    February 2017
  90. KAUFMANN H, Norcliffe-Kaufmann L, Palma JA, Biaggioni I, et al
    Natural history of pure autonomic failure: A United States prospective cohort.
    Ann Neurol. 2017;81:287-297.
    PubMed     Abstract available


    January 2017
  91. KORDOWER JH, Goetz CG, Chu Y, Halliday GM, et al
    Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient.
    Ann Neurol. 2017;81:46-57.
    PubMed     Abstract available


    December 2016
  92. PAGANO G, Niccolini F, Fusar-Poli P, Politis M, et al
    Serotonin transporter in Parkinson's disease: A meta-analysis of PET studies.
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24859.
    PubMed     Abstract available


  93. BRAKEDAL B, Haugarvoll K, Tzoulis C
    Simvastatin is associated with decreased risk of Parkinson Disease.
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24857.
    PubMed    


  94. YEN SJ, Lin KD
    Reply to "Simvastatin is associated with decreased risk of Parkinson Disease" by Brage Brakedal.
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24862.
    PubMed    


    October 2016
  95. LIN KD, Shin SJ
    Reply to 'Risk reduction of Parkinson disease by statin therapy in patients with diabetes' by T. Kawada.
    Ann Neurol. 2016 Oct 31. doi: 10.1002/ana.24813.
    PubMed    


  96. KAWADA T
    Risk reduction of Parkinson disease by statin therapy in patients with diabetes.
    Ann Neurol. 2016 Oct 27. doi: 10.1002/ana.24809.
    PubMed    


  97. STANDAERT DG, Geldmacher DS
    GBA, Parkinson disease, and the "senses and intellect".
    Ann Neurol. 2016 Oct 25. doi: 10.1002/ana.24808.
    PubMed    


  98. INZELBERG R, Flash S, Friedman E, Azizi E, et al
    Cutaneous malignant melanoma and Parkinson's disease: common pathways?
    Ann Neurol. 2016 Oct 19. doi: 10.1002/ana.24802.
    PubMed     Abstract available


    September 2016
  99. LIU G, Boot B, Locascio JJ, Jansen IE, et al
    Neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.
    Ann Neurol. 2016 Sep 22. doi: 10.1002/ana.24781.
    PubMed     Abstract available


  100. CILIA R, Tunesi S, Marotta G, Cereda E, et al
    Survival and dementia in GBA-associated Parkinson Disease: The mutation matters.
    Ann Neurol. 2016 Sep 15. doi: 10.1002/ana.24777.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: